Results 141 to 150 of about 35,072 (188)

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.

The Lancet, 2022
BACKGROUND Active-comparator trials are important to inform patient and physician choice. We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or adalimumab in biologic-naive patients with moderately to severely active ...
B. Sands, Peter M. Irving, T. Hoops, J. Izanec, Long-Long Gao, C. Gasink, A. Greenspan, M. Allez, S. Danese, S. Hanauer, V. Jairath, T. Kuehbacher, J. Lewis, Edward V. Loftus, E. Mihály, R. Panaccione, E. Scherl, Oksana B Shchukina, W. Sandborn   +18 more
semanticscholar   +1 more source

Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

Annals of the Rheumatic Diseases, 2022
Objectives To assess the risk of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) among patients initiating a Janus kinase inhibitor (JAKi) (tofacitinib and baricitinib) versus adalimumab in a large real-world ...
L. Hoisnard, Laura Pina Vegas, R. Dray-Spira, Alain Weill, Mahmoud Zureik, É. Sbidian   +5 more
semanticscholar   +1 more source

Adalimumab

American Journal of Clinical Dermatology, 2009
Adalimumab is a recombinant, human, IgG1 monoclonal antibody specific for tumor necrosis factor. The clinical efficacy and safety of adalimumab (40 mg administered subcutaneously every other week) in patients with moderate-to-severe chronic plaque psoriasis have been demonstrated in several randomized, double-blind clinical trials, including the ...
Katherine F, Croom, Paul L, McCormack
openaire   +3 more sources

Adalimumab

BioDrugs, 2007
Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). The clinical efficacy and safety of adalimumab in patients with moderate to severe Crohn's disease has been demonstrated in four pivotal, randomized, double-blind trials (CLASSIC-I, GAIN, CHARM, and CLASSIC-II) that ...
Greg L, Plosker, Katherine A, Lyseng-Williamson   +1 more
openaire   +3 more sources

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.

The Lancet, 2020
BACKGROUND Head-to-head trials in psoriatic arthritis are helpful in guiding clinical decision making. The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab as first-line biological monotherapy for 52 weeks in patients with ...
I. McInnes, F. Behrens, P. Mease, A. Kavanaugh, C. Ritchlin, P. Nash, J. G. Masmitjá, P. Goupille, T. Korotaeva, A. Gottlieb, Ruvie Martin, K. Ding, P. Pellet, S. Mpofu, L. Pricop   +14 more
semanticscholar   +1 more source

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial

Arthritis & Rheumatology, 2019
To evaluate the efficacy, including capacity for inhibition of radiographic progression, and safety of upadacitinib, a JAK1‐selective inhibitor, as compared to placebo or adalimumab in patients with rheumatoid arthritis (RA) who have experienced an ...
R. Fleischmann, A. Pangan, I. Song, E. Mysler, L. Bessette, C. Peterfy, P. Durez, A. Ostor, Yihan Li, Yijie Zhou, A. Othman, M. Genovese   +11 more
semanticscholar   +1 more source

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.

The Lancet, 2019
BACKGROUND Psoriasis is an autoimmune disease that affects approximately 100 million people worldwide, and is a disease that can be ameliorated by anti-cytokine treatment.
K. Reich, M. Gooderham, D. Thaçi, J. Crowley, C. Ryan, J. Krueger, T. Tsai, M. Flack, Yihua Gu, D. Williams, E. H. Thompson, C. Paul   +11 more
semanticscholar   +1 more source

Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children with Crohn's Disease Compared with Reactive Monitoring.

Gastroenterology, 2019
BACKGROUND & AIMS Proactive monitoring of drug trough concentrations and antibodies against drugs might help determine whether patients are likely to respond to treatment and increase efficacy.
A. Assa, M. Matar, D. Turner, E. Broide, B. Weiss, O. Ledder, A. Guz-Mark, F. Rinawi, Shlomi Cohen, C. Topf-Olivestone, R. Shaoul, B. Yerushalmi, R. Shamir   +12 more
semanticscholar   +1 more source

Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.

The Lancet Gastroenterology and Hepatology, 2021
BACKGROUND BI 695501 is a biosimilar that has demonstrated similar efficacy, safety, and immunogenicity to adalimumab reference product in patients with rheumatoid arthritis and chronic plaque psoriasis.
S. Hanauer, B. Liedert, S. Balser, E. Brockstedt, Viktoria Moschetti, S. Schreiber   +5 more
semanticscholar   +1 more source